HuMax-CD20: Phase I/II data

In an ongoing open-label, dose-escalation, European Phase I/II trial in 11 evaluable patients,

Read the full 139 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE